Carbon-Based Nanomaterials for Biomedicine Applications

Dear Colleagues,

As you know, nearly half a century after the discovery of fullerenes, countless publications have been devoted to the potential biomedical applications of carbon nanoparticles (CNPs), including nanotubes, nanohorns and, more recently, graphene. However, no such drug or medical device has yet legally entered the market. Obviously, it was the fear of the alleged dangers of CNPs instilled by certain authors in 2000 after the National Nanotechnology Initiative (NNI) in the USA, which was immediately spread by the media of the time, that was responsible for the sudden halt in the development of CNPs in the biomedical field and, even more seriously, the subsequent mistrust and disinterest of the pharmaceutical industry. Admittedly, the NNI originally called for investment in all S&T fields except toxicology and environmental impact.

Since then, it has taken several years for the scientific community to confirm that the toxicity observed with certain fullerene preparations can only be attributed to the impurities present in these preparations. Nevertheless, there is still a long way to go because, as with any drug candidate, the safety of each new CNP and/or formulation, as well as its fate in a living organism (ADME), must be tested before entering clinical trials.

The aim of this Special Issue is to provide a platform for expert groups, as well as young researchers, in this field to discuss the state of the art regarding the use of CNPs for diagnostic and/or therapeutic purposes. The underlying goal is to provide a springboard for renewed interest from researchers and potential investors in the healthcare sector.

All submissions, including, of course, those reporting proven toxic effects, in the form of research papers, analyses, commentaries, etc., will be accepted after peer review.

Prof. Dr. Fathi Moussa
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nanomaterials is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• carbon nanoparticles
• fullerenes
• nanotubes
• nanohorns
• graphene
• biomedical applications